The Second Attempt: Can Syndicate Bio Survive What 54gene Could Not?

The Second Attempt: Can Syndicate Bio Survive What 54gene Could Not?

What does it actually take to build a genomics company that lasts in Africa? 54gene had the thesis and $45M — and still collapsed. This episode breaks down Syndicate Bio's blueprint for getting it right: the right revenue, the right capital, and the decisions that turn a bold idea into a business that survives contact with pressure.

The Anatomy of a Biotech Collapse: What Killed 54gene?

For 54gene — the Nigerian genomics startup that raised forty-five million dollars before winding down in 2023 — the popular story has two versions. Version one: a frontier-market bet that got ahead of itself, with a founder who misread the room. Version two: a visionary scientist pushed out by predatory investors who stripped the company for parts. Both versions are incomplete. And on Per Visum, incomplete is not good enough.

Frontier Afrika Ep.1 Mispriced & Moving: Africa Is Not Waiting

Join us as we amplify the voice of emerging African markets through conversations on investments and policies — on Africa's own terms, with the people at the forefront.